ScreenerHero

ADAG Adagene Inc.

NAS · US · Healthcare · Biotechnology · adagene.com
2.810USD-4.10%Mkt Cap: 188.67M $P/E: —

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap188.67M USD
Enterprise Value91.46M USD
Revenue (TTM)9.29M USD
Gross Profit9.29M USD
Net Income (TTM)-17.61M USD
Revenue/Share0.18 USD
Last Price2.810 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees128
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.23
PEG—
EV/EBITDA-4.17
EV/Revenue9.84
P/S21.17
P/B2.20
EPS (TTM)-0.39
EPS (Forward)-0.56
52W Range
1.30043% of range4.850
52W High4.850 USD
52W Low1.300 USD
Profitability
Gross Margin100.00%
Oper. Margin-1023.92%
EBITDA Margin-236.28%
Profit Margin-229.56%
ROE-49.82%
ROA-22.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.66M USD
CapEx (TTM)17.05K USD
FCF Margin-130.87%
FCF Yield-6.44%
Net Debt-121.82M USD
Net Debt/EBITDA5.55
Balance Sheet
Debt/Equity0.18
Current Ratio5.02
Quick Ratio4.86
Book Value/Sh1.33 USD
Cash/Share1.91 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.908 USD
Upside (mean)+252.6%
Target Range7.000 USD – 17.45 USD
7.000+252.6% to mean17.45
# Analysts6
Ownership
Shares Out.67.14M
Float42.09M
Insiders11.39%
Institutions36.04%
Short Interest
Short Ratio8.9d
Short % Float3.68%
Short % Out.3.13%
Shares Short2.10M
Short (prev mo.)2.11M
Technical
SMA 503.556 (-21.0%)
SMA 2003.352 (-16.2%)
Beta0.54
S&P 52W Chg16.45%
Avg Vol (30d)222.67K
Avg Vol (10d)312.52K
Technical Indicators
RSI (14)36.5
MACD-0.1995
MACD Signal-0.1863
MACD Hist.-0.0132
BB Upper3.528 USD
BB Middle3.114 USD
BB Lower2.699 USD
BB Width26.64%
ATR (14)0.2830 USD
Vol Ratio (20d)0.67x